Draft Misuse of Drugs Act 1971 (Amendment) Order 2022

Debate between Stuart Andrew and Kit Malthouse

Thursday 27th January 2022 General Committees

[Kit Malthouse]

I am grateful to Members from across the Committee—particularly Opposition Members and the incoming Chair of the Select Committee, the right hon. Member for Kingston upon Hull North—for their support of the measure. As I hope people have understood, the draft order is part of a suite of tools that we are putting together as a general push against illicit drug use and the use of drugs in crime across the whole United Kingdom. Just before Christmas, we launched our 10-year drugs strategy, whose entire being is about driving down the pernicious effects of illicit drugs in the UK and the concomitant crime. This is a particularly pernicious and unpleasant area of business, on which we have become more focused recently—not least because, as a couple of Members pointed out, there has been a rise in the prevalence of the use of such drugs, and indeed in the number of deaths from it.

To answer the first question asked by the hon. Member for Bradford West, we do believe that the reclassification will reduce the use of the drugs, not least because the greater sentencing indicates a greater sense of priority, which will therefore attract greater police resource. The police prioritise their capacity on offences that we in this House deem to result in the highest harm, and they generally attract the highest amount of attention. For example, most murder squads will have 20 or 30 officers, while most burglary investigations will have one or two. By giving the matter such a level of importance, we think that greater attention will be paid to it. That includes, for example, sales of the compounds on the dark web, where we do enormous amounts of work, mostly thorough our National Crime Agency colleagues, on policing access to illicit equipment—guns, knives, chemicals or whatever it may be. Obviously, the draft order will help with that effort in directing them to where we think the most harm is emanating from.

The hon. Lady raised an interesting question about the use of the drugs consensually. Although there might be people who do that, I hope that everybody would agree that it is profoundly undesirable for their own health that they should use the drugs, whether they consent or not, given the effects that such compounds can have. They are effectively industrial solvents. They are not fit for human consumption. If we can discourage even that kind of use, we should.

Nevertheless, as the hon. Lady said, it is incumbent upon us to ensure that we have the right capacity and facilities in place for those who are victims of these kinds of sexually motivated crimes. As I hope she knows, just in the last couple of years we have expanded the number of independent sexual violence advisers and the support mechanisms available for people who are targeted by sexually motivated crime. On the wider response to the ACMD’s report, I would be more than happy to share that with her in due course.

I turn to the overall spiking strategy, although I am anxious not to expand beyond the general remit of the debate. The right hon. Member for Kingston upon Hull North identified spiking as a specific issue, and she is right that it is an area of concern. Last autumn, there was a significant rise in the number of reports of individuals who thought that they had been injected with these chemicals, rather than just consuming them in a drink. As she will know, given that she has spoken to Jason Harwin, a national gold group is looking at the evidence to ensure that we have right the capacity, and that we are linking up the right patterns and looking for the right clues about what might be happening with that phenomenon. It is widely the case that the number of convictions for spiking across the country, against the number of reports, has not been satisfactory over the last two or three years. I think that we would all admit that. I hope that the work that Jason is doing, alongside the wider drugs strategy, into which enormous resource is being pumped, particularly on health and rehabilitation, will start to drive down the usage.

The other effect that I ought to outline is that the raising of the classification of the drugs means that the proprietors of premises where they may be deployed, such as nightclubs, will need to be much more on their guard for such compounds as they arrive through the doors, as they are at the moment for cocaine, heroin and other drugs that sadly make their way into the night-time economy. We hope that the raising of the classification, and of the seriousness with which we take the issue, will be reflected in the law enforcement effort more generally across the country, and therefore we will see a reduction in the pernicious use of the chemicals. I commend the draft order to the Committee.

Question put and agreed to.

[The Treasurer of Her Majesty's Household (Stuart Andrew)]

On a point of order, Mr Hollobone. I will not detain the Committee for too long, but I bring it to your attention that the notifications that were sent out said that the start time of the meeting would be 11.30 am, not 11.25 am. Also, my hon. Friend the Member for Aylesbury (Rob Butler) received notification to be on the Committee, but is not a member of it. I wonder whether there has been some confusion with the hon. Member for Brent Central, who shares the same surname.

UK Science Budget

Debate between Stuart Andrew and Kit Malthouse

Wednesday 21st October 2015 Westminster Hall

[Stuart Andrew]

I have no choice—of course, I agree with the hon. Gentleman. He is right: this is about supporting the whole United Kingdom.

Evidence has shown that public sector investment in research encourages the private sector to invest too. Analysis has shown that an extra £1 of public funding would give rise to an increase in private funding of between £1.13 and £1.60.

The Government’s decision to protect science in 2010, at a time of significant savings, has been appreciated by the sector. It has enabled researchers to continue to push the boundaries of research and to transform exciting scientific discoveries into tangible benefits for patients and the economy. However, there are concerns that, with the true value of the science budget eroding, and with more savings in the pipeline, research could be at risk. Almost 200 life science organisations recently raised those concerns in a letter to the Chancellor.

Why should the Government invest in research? First, research saves lives. Across a number of different conditions, we have seen huge improvements in the range of treatments available, with people surviving conditions that would have been death sentences in the past. According to statistics from the British Heart Foundation, seven out 10 people now survive a heart attack.

The UK punches above its weight in terms of the outcomes its research sector achieves relative to the amount of money invested overall. On many measures, the sector is the most efficient in the world, and strikingly better than many of its competitors. The excellence of the UK science and research base results from universities’ autonomy and responsiveness; the competitive, dynamic funding system; the dual-support funding mechanism; an effective governance and research infrastructure; and the critical role played by universities in the science, research and innovation ecosystem.

[Kit Malthouse (North West Hampshire) (Con)]

Does my hon. Friend agree that, given the changing nature of the research model in the life sciences industry generally, it is even more vital that the Government maintain their investment in universities? Such is the burden of regulation and the investment model required by the private sector that molecules drugs therapies, often co-researched by the private sector, have to spend much more time in academia. If we withdraw funding at that stage, the research will simply not happen and will not transfer elsewhere.

[Stuart Andrew]

My hon. Friend raises an incredibly important and valid point, which emphasises the points I am making about Government investment in this important area.

An investment in research is an investment in our economy. The UK life sciences industry generates an estimated annual turnover of £56 billion and employs 183,000 people across the UK. Investment encourages innovation, attracts business to the UK and leads to treatments and technologies that allow us all to lead healthier, more productive lives.